Hydroxychloroquine is first-line at Yale because in-vitro data shows potent inhibition of the virus and possible clinical benefit, which is about as good as evidence gets at the moment, Indian American cardiologist Nihar Desai told the medical publication.May 02, 2020 at 08:24AM
from Top World News- News18.com https://ift.tt/3aSGBtf
No comments:
Post a Comment